ASX Health Stocks: Next Science jumps almost 10pc after XPERIENCE study published in science journal
Health & Biotech
Health & Biotech
Next Science (ASX:NXS) jumped almost 10% this morning after announcing the publication of a pilot study which demonstrates the utility of its flagship XPERIENCE solution in mitigating inflammation following a Total Knee Arthroplasty (TKA).
The XPERIENCE No Rinse Antimicrobial Solution is a surgical irrigation product. It is a clear, colourless solution intended for cleansing and removal of debris, including microorganisms from wounds.
The solution has proven efficacy against bacteria, and has been safety tested showing no irritation.
The publication announced today is based on the findings of a pilot study published on VuMedi (a video education platform for doctors) in August, which showed a potential anti-inflammatory benefit for XPERIENCE.
The findings were deemed important because it suggests an expanded application for XPERIENCE in addition to reducing biofilm-based infection rates.
The study findings have now undergone a peer review process, and been published in the Journal of Orthopaedic Experience & Innovation.
The article can be accessed via the link here.
“This publication means the study will now receive broader recognition in the Orthopaedic community,” said Next Science CEO, I.V. Hall.
“We will continue to work closely with surgeons to conduct clinical research that further investigates the effectiveness of Next Science’s products.”
Island Pharmaceuticals (ASX:ILA) has received approval to commence dosing the third cohort of its ISLA-101 Single Ascending Dose study.
ISLA-101 is a drug candidate being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.
The approval comes after a review of results from the second cohort concluded that the second dose was also safe and well-tolerated.
Island now expects screening of the third cohort to commence in January 2024, with final results on track for early 2024.
“This is very positive news to receive prior to the holiday period, and we are now looking forward to moving full steam ahead with screening cohort three in early January,” said Island CEO, Dr David Foster.
“Today’s news brings us one step closer to finalising the ISLA-101 Single Ascending Dose Study, and puts us in a strong position to move forward with our Phase 2a PEACH clinical trial.”
Clarity Pharmaceuticals (ASX:CU6) says the first patient has been dosed in the registrational Phase 3 prostate cancer trial (called CLARIFY) with Cu-64 SAR-bisPSMA.
The aim of the CLARIFY trial is to detect regional nodal metastases in participants with prostate cancer prior to radical prostatectomy.
The final results from the CLARIFY trial are intended to provide sufficient evidence to support an application to the FDA for the approval of the 64Cu-SAR-bisPSMA product in pre-prostatectomy patients.
Meanwhile, Radiopharm Theranostics (ASX:RAD) announced that the Site Initiation Visit (SIV) was successfully completed for the RAD 204 Phase 1 study in patients with Metastatic Non-small Cell Lung Cancer (NSCLC).
An SIV is required to prepare and set up a research site to conduct a study, and must occur prior to patient recruitment. The principal investigator must attend this visit together with as many members of the research team as possible.
RAD’s Phase 1 study is designed to evaluate safety and efficacy of 177Lu-RAD 204 in PD-L1-positive NSCLC patients, to be conducted at Princess Alexandra Hospital in Brisbane.
The first patient is expected to be dosed in January 2024.